Skip to main content
IMAGION BIOSYSTEMS LIMITED logo

IMAGION BIOSYSTEMS LIMITED — Investor Relations & Filings

Ticker · IBX ISIN · AU000000IBX6 ASX Professional, scientific and technical activities
Open in API
Filings indexed 658 across all filing types
Latest filing 2023-05-25 Capital/Financing Update
Country AU Australia
Listing ASX IBX

About IMAGION BIOSYSTEMS LIMITED

https://imagionbiosystems.com/

Imagion Biosystems Limited is a medical technology company specializing in the development of advanced diagnostic imaging solutions. The company's proprietary MagSense technology utilizes superparamagnetic iron oxide nanoparticles to detect specific cancer cells non-invasively. By functionalizing these nanoparticles with targeting antibodies, the system can identify the presence and location of malignancies, such as HER2-positive breast cancer, using highly sensitive magnetic sensors. This approach aims to provide a safer, more accurate alternative to traditional biopsy and imaging methods by eliminating the need for ionizing radiation or radioactive tracers. The technology is designed to improve clinical decision-making through earlier detection and better staging of diseases, ultimately enhancing patient outcomes in oncology.

Recent filings

Filing Released Lang Actions
Proposed issue of securities - IBX 6 pages 30.4KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from Imagion Biosystems Limited regarding a proposed issue of securities, specifically unlisted options. It details the number of securities, issue date, conditions, and purpose of the issue. The text references ASX Listing Rules and includes information typical of a capital raising or placement announcement. There are no financial statements or detailed financial performance data, so it is not an Annual Report or Interim Report. It is not a regulatory certification or voting result. The content clearly fits the category of a Capital/Financing Update, as it concerns a new securities issuance and related financing details.
2023-05-25 English
Cleansing Notice under Section 708A(12C)(e) 9 pages 234.3KB
Capital/Financing Update Classification · 95% confidence The document is a detailed Cleansing Notice issued under section 708A(12C)(e) of the Corporations Act 2001 (Cth) related to the issuance of the second tranche of convertible notes by Imagion Biosystems Limited. It includes detailed terms of the convertible notes, the effect on the company's capital structure, pro forma financial position, and rights attaching to shares issued upon conversion. The document is regulatory in nature, providing disclosure to enable resale of shares issued on conversion without further disclosure. It is not a financial report, earnings release, or management discussion, nor is it a meeting material or voting result. It is a formal regulatory announcement about a capital raising instrument and its implications. This fits best under Capital/Financing Update (CAP) as it updates on company fundraising and capital structure changes through convertible notes issuance.
2023-05-25 English
Chairman's Address to Shareholders 4 pages 131.2KB
AGM Information Classification · 95% confidence The document is titled 'AGM – Transcript of Chairman’s Address' and is dated 25 May 2023. It is addressed to shareholders and contains a detailed speech by the Chairman discussing the company's progress, clinical study results, strategic plans, and future outlook. The content is consistent with a presentation or speech given at an Annual General Meeting (AGM). There is no indication that this is a full annual report, financial statement, or regulatory filing. The document is a transcript of the Chairman's address at the AGM, which fits the definition of AGM Information (AGM-R). The document length (11,649 characters) supports that it is a full transcript rather than a brief announcement or summary. Therefore, the appropriate classification is AGM Information (AGM-R).
2023-05-24 English
AGM Investor Presentation 29 pages 4.9MB
Investor Presentation Classification · 95% confidence The document is titled 'AGM Investor Presentation 25 May 2023' and contains detailed information about the company's technology, clinical studies, market opportunities, and strategic highlights. It is structured as a presentation aimed at investors, with disclaimers and forward-looking statements typical of investor presentations. There is no indication that this is a full annual report, earnings release, or regulatory filing. The content is consistent with a detailed investor presentation typically shared at or around an Annual General Meeting (AGM). Therefore, the most appropriate classification is 'Investor Presentation' (IP).
2023-05-24 English
Results of Meeting 3 pages 148.3KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Results of Annual General Meeting' and provides detailed voting results for resolutions passed at the AGM of Imagion Biosystems Limited held on 25 May 2023. It references ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001, which govern disclosure of AGM voting results. The content includes proxy votes, votes for and against each resolution, and whether resolutions were carried. There is no financial data or report content, only the official announcement of voting outcomes. The document length is about 5,137 characters, which is consistent with a detailed voting results announcement rather than a full AGM presentation or annual report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-05-24 English
Change of Director's Interest Notices 15 pages 321.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by company directors, including the number of shares and options held before and after the change, dates of changes, and nature of changes such as expiration of listed options. The document is a formal notification of personal share transactions by company directors. It does not contain financial performance data, earnings, or management discussion, nor is it an announcement of a report publication. The content matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades).
2023-05-03 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.